Regeneron Pharma (REGN) 'High-Dose Eylea Data Far Exceeds Expectations, Supporting Franchise' - BMO
Tweet Send to a Friend
BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $788.00 price target on Regeneron Pharma (NASDAQ: REGN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
